(Ketamine + midazolam) is under clinical development by Melt Pharmaceuticals and currently in Phase III for Sedation. According to GlobalData, Phase III drugs for Sedation have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Ketamine + midazolam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Ketamine + midazolam) overview

A fixed dose combination of ketamine and midazolam (MELT-100) is under development for the treatment of conscious sedation in medical procedures, pain. The drug candidates are formulated as tablet and administered through sublingual route. Ketamine acts by targeting N-methyl-D-aspartate (NMDA) receptors and midazolam acts by targeting gamma-aminobutyric acid (GABA) A receptor. It is being developed based on Zydis delivery technology. 

It was also under development for acute claustrophobia.

Melt Pharmaceuticals overview

Melt Pharmaceuticals is a clinical-stage pharmaceutical company that is engaged in the development and commercialization of non-intravenous, non-opioid sedation and analgesia medicines. The company is headquartered in Brentwood, Tennessee, the US.

For a complete picture of (Ketamine + midazolam)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.